Vonoprazan in the management of erosive oesophagitis and peptic ulcer-induced medication: a systematic review

Introduction Vonoprazan has been found to promote a better antisecretory effect addressing acid-related diseases’ unmet needs. Aim: To assess if vonoprazan effectively treats patients diagnosed with gastroesophageal reflux disease esophagitis or with peptic ulcers induced by chronic use of aspirin o...

Full description

Saved in:
Bibliographic Details
Published in:Przegląd gastroenterologiczny 2022-01, Vol.17 (3), p.183-189
Main Authors: Chinzon, Décio, P. Moraes-Filho, Joaquim Prado, Domingues, Gerson, Soares Guedes, Juliana Leite, Yang Santos, Cláudia, Zaterka, Schlioma
Format: Article
Language:English
Subjects:
Acids
Analgesics
Anti-inflammatory agents
Aspirin
Bias
Chronic illnesses
Clinical trials
Cohort analysis
Disease
Drug dosages
Gastroenterology
Gastroesophageal reflux
Potassium
Quality of life
Review Paper
Systematic review
Ulcers
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction Vonoprazan has been found to promote a better antisecretory effect addressing acid-related diseases’ unmet needs. Aim: To assess if vonoprazan effectively treats patients diagnosed with gastroesophageal reflux disease esophagitis or with peptic ulcers induced by chronic use of aspirin or non-steroidal anti-inflammatory drugs. Material and methods A literature search was conducted (April/2021) using Medline via PubMed, Cochrane library, Lilacs, Scielo, and Centre for Reviews and Dissemination electronic databases. Results We retrieved 55 titles. Of these, 13 met the eligibility criteria and were included in this review. Of these 13 articles, 4 were prospective cohort studies, 1 was a follow-up analysis of a preceding prospective study, 1 was a retrospective cohort study, and 6 were randomized clinical trials. Conclusions Our findings suggest that vonoprazan was effective and non-inferior to proton pump inhibitors in healing and maintaining healed reflux oesophagitis, leading to faster symptom relief. Vonoprazan may also be considered for preventing aspirin- or non-steroidal anti-inflammatory drug-related peptic ulcer recurrence.
ISSN:1895-5770
1897-4317
DOI:10.5114/pg.2021.111401